Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel Antiviral Therapeutic Platform: Anchoring IFN-β to the Surface of Infectious Virions Equips Interferon-Evasive Virions with Potent Antiviral Activity.

Viruses·2025
Same author

Soluble CD25 imposes a low-zone IL-2 signaling environment that favors competitive outgrowth of antigen-experienced CD25<sup>high</sup> regulatory and memory T cells.

Cellular immunology·2023
Same author

Early Post-Vaccination Gene Signatures Correlate With the Magnitude and Function of Vaccine-Induced HIV Envelope-Specific Plasma Antibodies in Infant Rhesus Macaques.

Frontiers in immunology·2022
Same author

Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection.

mSphere·2022
Same author

Different adjuvanted pediatric HIV envelope vaccines induced distinct plasma antibody responses despite similar B cell receptor repertoires in infant rhesus macaques.

PloS one·2021
Same author

SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques.

Science immunology·2021
Same journal

Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan's pediatric National Immunization Program and impacts of a delayed implementation.

Human vaccines & immunotherapeutics·2026
Same journal

Safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trial.

Human vaccines & immunotherapeutics·2026
Same journal

Randomized controlled trial evaluating immunogenicity and safety of a porcine circovirus-free rotavirus vaccine in healthy Chinese infants.

Human vaccines & immunotherapeutics·2026
Same journal

Determinants of HPV vaccination acceptance among young adult women in Japan's catch-up generation: A cross-sectional study.

Human vaccines & immunotherapeutics·2026
Same journal

Spatial accessibility analysis of vaccination units in Gansu Province, China (2025).

Human vaccines & immunotherapeutics·2026
Same journal

Pneumococcal vaccination awareness and uptake among high-risk patients attending internal medicine outpatient clinics: A cross-sectional study.

Human vaccines & immunotherapeutics·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

Tolerogenic vaccines for Multiple sclerosis.

Mark D Mannie1, Alan D Curtis

  • 1Department of Microbiology and Immunology; Brody School of Medicine; East Carolina University; Greenville, NC USA.

Human Vaccines & Immunotherapeutics
|January 30, 2013
PubMed
Summary
This summary is machine-generated.

Tolerogenic vaccines aim to reverse autoimmune diseases like Multiple Sclerosis by restoring immune balance. These vaccines create lasting immune memory to block harmful T cell responses, offering future therapeutic potential.

Keywords:
T lymphocytesautoimmune diseaseexperimental autoimmune encephalomyelitisimmunemultiple sclerosismyelinneuroantigentherapytolerancevaccine

More Related Videos

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice

Published on: April 15, 2014

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Experiment Videos

Last Updated: May 14, 2026

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice

Published on: April 15, 2014

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Area of Science:

  • Immunology
  • Vaccinology
  • Neuroimmunology

Background:

  • Autoimmune diseases, such as Multiple Sclerosis (MS), involve immune system attacks on self-tissues.
  • Current treatments for MS often manage symptoms but do not restore immune homeostasis.
  • Tolerogenic vaccines offer a novel approach to re-establish self-tolerance and potentially reverse autoimmune conditions.

Purpose of the Study:

  • To provide an overview of current concepts in tolerogenic vaccination for Multiple Sclerosis.
  • To discuss the future prospects and potential therapeutic benefits of tolerogenic vaccines in MS.
  • To identify key challenges hindering the clinical application of tolerogenic vaccines for MS.

Main Methods:

  • Review of preclinical studies demonstrating the efficacy of tolerogenic vaccines.
  • Analysis of mechanisms by which tolerogenic vaccines induce antigen-specific immune tolerance.
  • Discussion of strategies for translating tolerogenic vaccine concepts into clinical MS therapies.

Main Results:

  • Tolerogenic vaccines induce antigen-specific, long-term inhibitory immune memory.
  • These vaccines promote the loss of pathogenic T cells and the gain of regulatory T cell function.
  • Preclinical models of experimental autoimmune encephalomyelitis show significant inhibition by tolerogenic vaccines.

Conclusions:

  • Tolerogenic vaccines show promise for treating Multiple Sclerosis by restoring immune tolerance.
  • Advances in preclinical settings suggest a potential therapeutic role for these vaccines in MS.
  • Overcoming challenges in clinical application is crucial for realizing the full potential of tolerogenic vaccination in MS.